Evidence map›Paper›PMID 34239768›Full record

ReviewMedeniyet medical journal2021

Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives.

Panoraia Siafaka, Esra Ipekci, Emre Şefik Caglar, Neslihan Ustundag Okur, Derya Buyukkayhan

Abstract readReview
In one paragraph

Review in Medeniyet medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Panoraia SiafakaAristotle University of Thessaloniki, Department of Chemistry, Thessaloniki, Greece.ORCID https://orcid.org/0000-0003-0317-4113
Esra IpekciUniversity of Health Sciences, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-0884-764X
Emre Şefik CaglarUniversity of Health Sciences, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-6975-8096
Neslihan Ustundag OkurUniversity of Health Sciences, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-6975-8096
Derya BuyukkayhanUniversity of Health Sciences, Faculty of Medicine, Department of Pediatrics, Division of Neonatology, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-7172-0812

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infants and other children can be affected by various acute, chronic and many of them rare illnesses. Developing drugs for children is very challenging since they cannot intake tablets or hard oral solid dosage forms. Besides, most of the prescribed pediatric medications are unlicensed. The biggest issue that clinicians have to solve is that dosing in children is not based on weight or surface area of the body, as it happened in adults but is related to age variations in drug absorption, distribution, metabolism, and elimination. Thus, for pediatric patients, various therapeutic approaches have been proposed so as to develop suitable formulations such as liquid dosage forms, flexible capsules, milk-based products, etc. In addition, the administration of current pharmaceutical products to children might lead to some serious side effects which can also happen in adults but with a lower risk. Especially, infants are at high risk of getting poisoned by taking drugs used for adults. Moreover, children are very sensitive to the taste and smell of some pharmaceutical vehicles and can resist to intake them and this situation leads parents to search for tasteless and odorless medications. In this study, the current formulations for various diseases intended to be used in pediatric patients as well as various chronic and acute diseases of childhood are summarized. Authors believe that this review can help professionals who want to work with pediatric formulations to design more efficient and child-friendly drug delivery systems.

Indexed as

childrendrug delivery systemsinfantsPediatric diseasespediatric formulationspharmaceutical technology

Identifiers

PMID34239768
PMCPMC8226405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.